Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy-Reference-Cited by-同舟云学术

Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy

Published:2022-06-10 Issue:7 Volume:13 Page:1281-1298
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

González-Clemente José M.,García-Castillo María,Gorgojo-Martínez Juan J.,Jiménez Alberto,Llorente Ignacio,Matute Eduardo,Tejera Cristina,Izarra Aitziber,Lecube Albert

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-022-01280-6.pdf

Reference74 articles.

1. Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135–46. https://doi.org/10.1007/s40265-019-01148-3.

2. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90. https://doi.org/10.1111/j.1463-1326.2011.01517.x.

3. European Medicines Agency. Forxiga. https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga. Accessed Apr 30, 2022.

4. US Food And Drug Administration. Drugs@FDA: FDA-Approved Drugs. Farxiga. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202293. Accessed Apr 30, 2022.

5. van Bommel EJM, Smits MM, Ruiter D, et al. Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. J Hypertens. 2020;38(9):1811–9. https://doi.org/10.1097/HJH.0000000000002480.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of dapagliflozin on cardiovascular remodeling in hypertensive patients with accompanying type 2 diabetes;Pathologia;2024-04-22

2. SGLT2i improves kidney senescence by down‐regulating the expression of LTBP2 in SAMP8 mice;Journal of Cellular and Molecular Medicine;2024-03

3. Exploration of Pharmacological Mechanisms of Dapagliflozin against Type 2 Diabetes Mellitus through PI3K-Akt Signaling Pathway based on Network Pharmacology Analysis and Deep Learning Technology;Current Computer-Aided Drug Design;2024-01-09

4. Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-01

5. In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats;Biomedicine & Pharmacotherapy;2023-06